In a pivotal moment for the materials industry, Australian start-up Uluu has secured AU$16 million in its Series A funding round to build a demonstration facility capable of scaling its seaweed-derived plastic alternative. Headquartered in Perth, Western Australia, the company plans to move from its current 100 kg/year pilot plant to a 10-tonne/year demonstration plant…
For a biotech world often focused on oncology and gene editing, Hemab Therapeutics has carved out a very different frontier: rare, inherited bleeding disorders that have long gone overlooked. The company has raised $157 million in a Series C round, a multifold oversubscribed financing led by Sofinnova Partners, with participation from a global sovereign wealth…
When biotech firm VitriVax raised $17.25 million in a Series B funding round, co-led by Adjuvant Capital and RA Capital Management, LP, it revealed more than just money changing hands—it spotlighted a broader fracture point in global immunisation strategy. Based in Boulder, Colorado, VitriVax is tackling two fundamental hurdles in vaccine delivery: the cold-chain barrier and the logistical burden…
In the complex world of immune-mediated diseases, where treatment options often fall short, Electra Therapeutics is carving a distinct path. The late-stage biotech, based in the U.S., has secured a robust $183 million in Series C funding to advance its groundbreaking precision therapies targeting severe immunological conditions and hematologic cancers. The financing round, co-led by…
In a crowded biotech landscape where antibiotic breakthroughs rarely break through, Peptilogics has secured a commanding $78 million in an oversubscribed Series B2 round to fuel its pivotal trial of zaloganan (PLG0206), a therapeutic candidate aimed at prosthetic joint infections (PJI). The financing was led by Presight Capital, Thiel Bio, and Founders Fund, with fresh capital from…
BridGene Biosciences, a San Jose–based biotech innovator focused on tackling traditionally “undruggable” molecular targets, has raised $28 million in a Series B+ funding round led by Bayland Capital. This capital injection will accelerate clinical advancement of BridGene’s lead candidate, BGC-515—a covalent TEAD inhibitor aimed at solid tumors—and fuel expansion of its proprietary IMTAC™ chemoproteomic platform…
In a decisive move for the interventional oncology space, ABK Biomedical has closed an oversubscribed US$35 million Series D round, led by J.P. Morgan Life Sciences Private Capital. Longtime backers including F‑Prime, Santé Ventures, Eight Roads Ventures, and a strategic but undisclosed medical device player also participated. The fresh capital will underwrite the clinical operations…
In a significant milestone for antibiotic innovation, Blacksmith Medicines has been granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration (FDA) for its novel antibiotic candidate, FG-2101. This small molecule inhibitor targets LpxC, a metalloenzyme essential to the survival of Gram-negative bacteria, including multidrug-resistant strains—an area…
EVerZom, a pioneering biotechnology firm based in France, has secured €10 million in a Series A funding round to propel the clinical development of its first therapeutic candidate and further scale its exosome biomanufacturing platform. The investment, which brings together major players like Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by…
A new force has entered the allergy‑therapeutics arena. Excellergy has announced a bold $70 million Series A round designed to advance its lead candidates—“trifunctional” Effector Cell Response Inhibitors (ECRIs)—toward clinical proof. The molecules aim to simultaneously strip IgE from bound immune cells, neutralize free IgE, and tamp down the receptor expression that fuels allergic cascades….
